Effect of quercetin on the genotoxic potential of cisplatin

International Journal of Cancer

Volumn 66, Issue 3, 1996, Pages 404-408

  Cross, Hilary J ^a,b   Tilby, Michael ^c   Chipman, J Kevin ^b   Ferry, David R ^b   Gescher, Andreas ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; QUERCETIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; GENOTOXICITY; LIVER CELL; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SALMONELLA TYPHIMURIUM;

ANIMALS; ANTINEOPLASTIC AGENTS; CELLS, CULTURED; CISPLATIN; DNA; DNA ADDUCTS; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; KINETICS; LIVER; MICROBIAL SENSITIVITY TESTS; MUTAGENS; QUERCETIN; RATS; SALMONELLA TYPHIMURIUM; THYMIDINE;

EID: 0029954041     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960503)66:3<404::AID-IJC23>3.0.CO;2-9     Document Type: Article

References (43)

1. AHMED, M.S., RAMESH, V., NAGARJA, V., PARISH, J.H. and HADI, S.M., Mode of binding of quercetin to DNA. Mutagenesis, 9, 193-197 (1994).
2. ALLDRICK, A.J., LAKE, B.G. and ROWLAND, I.R., Modification of in vivo heterocyclic amine genotoxicity by dietary flavonoids. Mutagenesis, 4, 365-370 (1989).
3. ANDERSON, K.S., Platinum(II) complexes generate frameshift mutations in test strains of Salmonella typhimurium. Mutation Res., 76, 209-214 (1979).
4. AVILA, M.A., VELASCO, J.A., CANSADO, J. and NOTARIO, V., Quercetin mediates the downregulation of mutant p53 in the human breast cancer cell line MDA MB468. Cancer Res., 54, 2424-2428 (1994).
5. BECK, D.J. and FISCH, J.E., Mutagenicity of platinum coordination complexes in Salmonella typhimurium. Mutation Res., 77, 45-54 (1980).
6. BERRY, M.N. and FRIEND, D.S., High-yield preparation of isolated rat liver parenchymal cells. J. Cell Biol., 43, 506-520 (1969).
7. BRADLEY, L.J.N., YAREMA, K.J., LIPPARD, S.J. and ESSIGMANN, J.M., Mutagenicity and genotoxicity of the major DNA adduct of the antitumor drug cis-diamminedichloroplatinum. Biochemistry, 32, 982-988 (1993).
8. BROWN, J.P., A review of the genetic effects of naturally occurring flavonoids, anthraquinones and related compounds. Mutation Res., 75, 243-277 (1980).
9. CZECTOT, H., TUDEK, B., KUSZTELAK, J., SZYMCZVK, T., DOBROWOLOSKA, B., GLINKOWSKA, G., MALINOWSKI, A. and STRZELECKA, H., Isolation and studies of the mutagenic activity in the Ames test of flavonoids naturally occurring in medical herbs. Mutation Res., 240, 209-216 (1990).
10. DUNNET, C.W., A multiple comparison procedure for comparing several treatments with a control. Amer. Statist. Assoc J., 50, 1096-1121 (1955).
11. EVANS, D.L , TILBY, M. and DIVE, C., Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. Cancer Res., 54, 1596-1603 (1994).
12. EVANS, W.C., PATEL, M.C, and KOOHY, Y., Acute bracken poisoning in homogastric and ruminant animals. Proc. Roy. Soc. (Edinburgh), 81, 29-64 (1982).
13. FERRY, D., SMITH, A., MALKHANDI, J., FYFE, D.W., DETAKATS, P., ANDERSON, D., BAKER, J. and KERR, D.J., Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. Clin. Cancer Res. (1996) (In press).
14. FRAM, R.J., CUSIEK, P.S. and MARINUS, M.G., Studies on mutagenesis and repair induced by platinum analogues. Mutation Res., 175, 13-18 (1986).
15. GORE, M.E., FRYATI, I., WILTSHAW, E., DAWSON, T., ROBINSON, B.A. and CALVERT, A.H., Cisplatin/carboplatin cross resistance in ovarian cancer. Brit. J. Cancer, 60, 767-769 (1989).
16. GSCHWENDT, M., HORN, F., KITTSTEIN, W. and MARKS, F., Inhibition of the calcium- and phospholipid-dependent protein kinase activity from mouse brain cytosol by quercetin. Biochem. biophys. Res. Comm., 117, 444-447 (1983).
17. HAGIWARA, M., INOUE, S., TANAKA, T., NUNOKI, K., ITO, M. and HIDAKA, H., Differential effects of flavonoids as inhibitors of tyrosine protein kinases and serine/threonine protein kinases. Biochem. Pharmacol., 37, 2987-2992 (1988).
18. HANNAN, M.A., AL-DAKAN, A.A., HUSSAIN, S.S. and AMER, M.H., Mutagenicity of cisplatin and carboplatin used alone and in combination with four other anticancer drugs. Toxicology, 55, 183-191 (1989).
19. HERTOG, M.B.H., HOLLMAN, P.G.H., KATAN, M.B. and KROMHOUT, D., Intake of potentially anticarcinogenic flavonoids and their determinants in adults in The Netherlands. Nutr. Cancer, 20, 20-21 (1993).
20. HOFMANN, J., DOPPLER, W., JAKOB, A., MALY, K., POSCH, L., ÜBERALL, F. and GRUNICKE, H.H., Enhancement of the antiproliferative effect of cis-diamminedichloroplatinum(II) and nitrogen mustard by inhibitors of protein kinase C. Int. J Cancer, 42, 382-388 (1988).
21. HOFMANN, J., FIEBIG, H.H., WINTERHALTER, B.R., BERGER, D.P. and GRÜNICKE, H.H., Enhancement of the antiproliferative activity of cis-diamminedichloroplatinum(II) by quercetin. Int. J. Cancer. 45, 536-539 (1990).
22. HUANG, M.T., WOOD, A.W., NEWMARK, H.L., SAYER, J.M., YAGI, H., JERINA, D.M. and CONNEY, A.H., Inhibition of the mutagenicity of bay-region diol-epoxides of polycylic aromatic hydrocarbons by phenolic plant flavonoids. Carcinogenesis, 4, 1631-1637 (1983).
23. ITO, N., Is quercetin carcinogenic? Jpn. J. Cancer Res., 83, 312-314 (1992).
24. LEOPOLD, W.R., MILLER, E.C. and MILLER, J.A., Carcinogenicity of antitumor cisplatinum(II) coordination complexes in the mouse and rat. Cancer Res., 39, 913-918 (1979).
25. MADLE, S., DEAN, S.W., ANDRAE, U., BRAMBILLA, G., BURLINSON, B., DOOLITTLE, D.J., FURIHATA, C., HERTNER, T., MCQUEEN, C.A. and MORI, H., Recommendations for the performance of UDS tests in vitro and in vivo. Mutation Res., 312, 263-285 (1994).
26. MACGREGOR, J.T. and WILSON, R.E., Flavone mutagenicity in Salmonella typhimurium: dependence on the pKM101 plasmid and excisionrepair deficiency. Environ. mol. Mutagenesis. 11, 315-322 (1988).
27. MARON, D.M. and AMES, B.N., Revised methods for the Salmonella mutagenicity test. Mutation Res., 113, 173-215 (1983).
28. MOLDEUS, P., HOGBERG, J. and ORRENIUS, S., Isolation and use of liver cells. Methods Enzymol., 52, 60-71 (1978).
29. OGAWA, S., HIRAYAMA, T , SUMIDA, Y., TOKUDA, M., HIRAJ, K. and FUKUI, S., Enhancement of the mutagenicity of 2-acetylaminofluorene by flavonoids and structural requirements. Mutation Res., 190, 107-112 (1987).
30. ONO, K. and KAKANE, H., Mechanisms of inhibition of various cellular DNA and RNA polymerases by several flavonoids. J. Biochem., 108, 609-613 (1990).
31. RUEFF, J., LAIRES, A., GASPAR, J., BORBA, H. and RODRIGUES, A., Oxygen species and the genotoxicity of quercetin. Mutation Res., 265, 75-81 (1992).
32. SANDHU, P. and CHIPMAN, J.K., Bacterial mutagenesis and hepatocyte unscheduled DNA synthesis induced by chrysoidine azo-dye components. Mutation Res., 240, 227-236 (1990).
33. SCAMBIA, G., RANALLETTI, F.O., BENEDETTI-PANICI, P., BONANNO, G., DE VINCENZO, R , FERRANDINA, G., PIERELLI, L., CAPELLI, A. and MANCUSO, S., Quercetin inhibits the growth of a multidrug-resistant estrogen-receptor-negative MCF-7 human breast cancer cell line expressing type II estrogen binding sites. Cancer Chemother. Pharmacol., 28, 255-258 (1991).
34. SCAMBIA, G., RANALLETTI, F.O., BENEDETTI-PANICI, P., BONANNO, G., DE VINCENZO, R., PIANTELLI, M. and MANCUSO, S., Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth. Anti-Cancer Drugs, 1, 45-48 (1990c).
35. SCAMBIA, G., RANALLETTI, F.O., BENEDETTI-PANICI, P., PIANTELLI, M., BONANNO, G., DE VINCENZO, R., FERRANDINA, G., MAGGIANO, N., CAPELLI, A. and MANCUSO, S., Inhibitory effect of quercetin on primary ovarian and endometrial cancers and synergistic activity with cis-diamminedichloroplatinum(II). Gynecol. Oncol., 45, 13-19 (1992).
36. SCAMBIA, G., RANALLETTI, F.O., BENEDETTI-PANICI, P., PIANTELLI, M., BONANNO, G., DE VINCENZO, R., FERRANDINA, G., RUMI, C., LAROCCA, L.M. and MANCUSO, S., Inhibitory effect of quercetin on OVCA 433 cells and presence of type II oestrogen binding sites in primary ovarian tumours and cultured cells. Brit. J. Cancer. 62, 942-946 (1990b).
37. TILBY, M.J., JOHNSON, C., KNOX, R.J., CORDELL, J. and DEAN, C.J., Sensitive detection of DNA modifications induced by cisplatin and carboplatin in vitro and in vivo using a monoclonal antibody. Cancer Res., 51, 123-129 (1991).
38. UNO, Y. and MORITA, M., Mutagenic activity of some platinum and palladium complexes. Mutation Res., 298, 269-275 (1993).
39. VERMA, A., JOHNSONS, J.A., GOULD, M.N. and TANNER, M.A., Inhibition of 7,12-dimethylbenz-(a)anthracene- and N-methylnitrosourea-induced rat mammary cancer by the dietary flavonoid quercetin. Cancer Res., 48, 5754-5758 (1988).
40. WAHRENDORF, J., MAHON, G.A.T. and SCHUMACHER, M., A non-parametric approach to the statistical analysis of mutagenicity data. Mutation Res., 147, 5-13 (1985).
41. WEI, Y.Q., ZHAO, X., KARIYA, Y., FUKATA, H., TESHIGAWARA, K. and UCHIDA, A., Induction of apoptosis by quercetin: involvement of heat shock protein. Cancer Res., 54, 4952-4957 (1994).
42. YAREMA, K.J., WILSON, J.M., LIPPARD, S.J. and ESSIGMANN, J.M., Effects of DNA adduct structure and distribution on the mutagenicity and genotoxicity of two platinum anticancer drugs. J. med. Chem., 236, 1034-1048 (1994).
43. YOSHIDA, M., SAKAI, T., HOSOKAWA, N., MARUI, N., MATSUMOTO, K., FUJIOKA, A., NISHINO, H. and AOIKE, A., The effects of quercetin on cell cycle progression and growth of human gastric cancer cells. FEBS Lett., 260, 10-13 (1990).